Matrix Asset Advisors Inc. NY Sells 195,980 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Matrix Asset Advisors Inc. NY decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 54.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 167,009 shares of the biopharmaceutical company’s stock after selling 195,980 shares during the quarter. Matrix Asset Advisors Inc. NY’s holdings in Gilead Sciences were worth $10,323,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of GILD. Rockefeller Capital Management L.P. lifted its stake in Gilead Sciences by 3.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 142,703 shares of the biopharmaceutical company’s stock valued at $10,361,000 after acquiring an additional 4,480 shares in the last quarter. Mutual Advisors LLC boosted its stake in Gilead Sciences by 9.2% in the 4th quarter. Mutual Advisors LLC now owns 20,841 shares of the biopharmaceutical company’s stock worth $1,513,000 after purchasing an additional 1,753 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in shares of Gilead Sciences by 3.9% during the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 17,428 shares of the biopharmaceutical company’s stock valued at $1,265,000 after acquiring an additional 648 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in shares of Gilead Sciences during the 4th quarter valued at about $73,000. Finally, LPL Financial LLC lifted its position in Gilead Sciences by 7.7% in the 4th quarter. LPL Financial LLC now owns 767,837 shares of the biopharmaceutical company’s stock worth $55,753,000 after buying an additional 54,957 shares during the last quarter. Institutional investors and hedge funds own 78.58% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $0.94 during trading hours on Friday, hitting $62.83. 188,695 shares of the stock were exchanged, compared to its average volume of 7,683,103. The company has a debt-to-equity ratio of 1.30, a current ratio of 1.43 and a quick ratio of 1.27. The company’s 50 day moving average is $63.22 and its 200 day moving average is $62.02. The firm has a market capitalization of $78.75 billion, a P/E ratio of 19.44, a P/E/G ratio of 0.61 and a beta of 0.31. Gilead Sciences, Inc. has a one year low of $57.17 and a one year high of $74.12.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.07. Gilead Sciences had a net margin of 15.03% and a return on equity of 42.92%. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $5.88 billion. On average, research analysts expect that Gilead Sciences, Inc. will post 6.63 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Thursday, September 15th will be issued a dividend of $0.73 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.92 annualized dividend and a yield of 4.65%. Gilead Sciences’s dividend payout ratio (DPR) is currently 89.02%.

Analyst Upgrades and Downgrades

GILD has been the topic of several research analyst reports. SVB Leerink reissued a “market perform” rating on shares of Gilead Sciences in a research note on Thursday, September 15th. Piper Sandler upped their target price on shares of Gilead Sciences from $74.00 to $79.00 in a research note on Monday, September 12th. StockNews.com downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 17th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, July 12th. They issued a “neutral” rating and a $70.00 price target for the company. Finally, Morgan Stanley increased their price target on Gilead Sciences from $63.00 to $65.00 and gave the company an “equal weight” rating in a research note on Friday, July 15th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Hold” and an average target price of $73.53.

About Gilead Sciences

(Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.